BR112022018440A2 - Tratamento com epinefrina intranasal em pó - Google Patents

Tratamento com epinefrina intranasal em pó

Info

Publication number
BR112022018440A2
BR112022018440A2 BR112022018440A BR112022018440A BR112022018440A2 BR 112022018440 A2 BR112022018440 A2 BR 112022018440A2 BR 112022018440 A BR112022018440 A BR 112022018440A BR 112022018440 A BR112022018440 A BR 112022018440A BR 112022018440 A2 BR112022018440 A2 BR 112022018440A2
Authority
BR
Brazil
Prior art keywords
treatment
intranasal
intranasal epinephrine
dry powder
powder form
Prior art date
Application number
BR112022018440A
Other languages
English (en)
Inventor
Temtsin-Krayz Galia
Kazhdan Pavel
Original Assignee
Nasus Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasus Pharma Ltd filed Critical Nasus Pharma Ltd
Publication of BR112022018440A2 publication Critical patent/BR112022018440A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

TRATAMENTO COM EPINEFRINA INTRANASAL EM PÓ. É divulgada uma composição farmacêutica na forma de pó seco para administração intranasal, compreendendo um agonista de receptor adrenérgico anti-anafilático na forma de pó seco para administração intranasal, a composição compreendendo partículas sólidas do agente ativo em combinação com pelo menos um aditivo funcional e partículas sólidas de um carreador inerte.
BR112022018440A 2020-03-16 2021-03-16 Tratamento com epinefrina intranasal em pó BR112022018440A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
PCT/IL2021/050288 WO2021186437A1 (en) 2020-03-16 2021-03-16 Treatment with powdered intranasal epinephrine

Publications (1)

Publication Number Publication Date
BR112022018440A2 true BR112022018440A2 (pt) 2022-11-01

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018440A BR112022018440A2 (pt) 2020-03-16 2021-03-16 Tratamento com epinefrina intranasal em pó

Country Status (13)

Country Link
US (2) US11400045B2 (pt)
EP (1) EP4121005A1 (pt)
JP (1) JP2023517532A (pt)
KR (1) KR20220154709A (pt)
CN (1) CN115279340A (pt)
AR (1) AR121593A1 (pt)
AU (1) AU2021239084A1 (pt)
BR (1) BR112022018440A2 (pt)
CA (1) CA3175130A1 (pt)
IL (1) IL296268A (pt)
MX (1) MX2022011464A (pt)
TW (1) TW202200119A (pt)
WO (1) WO2021186437A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526098A (ja) 2020-05-18 2023-06-20 オレクソ・アクチエボラゲット 薬物送達のための新しい医薬組成物
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
WO2024031148A1 (en) * 2022-08-11 2024-02-15 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
US20160220489A1 (en) 2013-09-03 2016-08-04 G2B Pharma Inc. Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
CA2971440C (en) * 2014-12-18 2024-02-13 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
JP7334145B2 (ja) 2017-08-20 2023-08-28 ネイサス ファーマ リミテッド 鼻腔内送達用乾燥粉末組成物
DE112019000683T5 (de) * 2018-02-06 2020-10-15 Aegis Therapeutics, Llc Intranasale epinephrin-formulierungen und verfahren zur behandlung von erkrankungen

Also Published As

Publication number Publication date
CN115279340A (zh) 2022-11-01
KR20220154709A (ko) 2022-11-22
MX2022011464A (es) 2022-11-14
US20210283050A1 (en) 2021-09-16
TW202200119A (zh) 2022-01-01
US20230105615A1 (en) 2023-04-06
IL296268A (en) 2022-11-01
CA3175130A1 (en) 2021-09-23
JP2023517532A (ja) 2023-04-26
US11400045B2 (en) 2022-08-02
AU2021239084A1 (en) 2022-10-13
WO2021186437A1 (en) 2021-09-23
EP4121005A1 (en) 2023-01-25
AR121593A1 (es) 2022-06-22

Similar Documents

Publication Publication Date Title
BR112022018440A2 (pt) Tratamento com epinefrina intranasal em pó
BR112018012697A2 (pt) sistemas e métodos para produzir pó consumível
BR112013020509A2 (pt) artigo de fumo
BR112015024901A2 (pt) partículas abrasivas tendo formas particulares e métodos para formar essas partículas
BR112015028326A8 (pt) combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
BR112016023844A2 (pt) artigo abrasivo incluindo partículas abrasivas moldadas
BR112013010515A2 (pt) partículas de grafeno revestidas de diamante, composições e estruturas intermédias compreendendo o mesmo e os métodos de formação de poli cristalinos de partículas de diamante grafeno-revestido e compactos
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
BR112019006488A2 (pt) artigos formados de materiais de base de polpa com liberação de aroma modulada
BR112018015838A2 (pt) composição de vulcanização, composto de ciclododecaenxofre, formulação elastomérica vulcanizável, mistura padrão de agente de vulcanização, e, artigo elastomérico vulcanizado.
BR112022023307A2 (pt) Composição farmacêutica para entrega de fármacos
EP4331607A3 (en) Pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
BR112014012711A2 (pt) preservativo revestido
BR112017004306A2 (pt) matéria-prima pulverizada pré-formulada
CL2008003802A1 (es) Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple.
BR112019004126A2 (pt) adaptador de elemento de inserção para particionar que tem um eixo geométrico de índice de adaptador e montagem de ferramenta
CR20190125A (es) Combinación de agonistas de fxr
BR112017026127A2 (pt) ferramenta de corte giratória
BR112015018485A2 (pt) composição de sulfonato de olefina interna
BR112016024225A2 (pt) artigo moldado formado de material reciclado após uso
AR058107A1 (es) Azodicarbonamida micronizada, su preparacion y su utilizacion
CL2021000931A1 (es) Conjunto de desgaste
BR112019006002A2 (pt) filamento à base de propileno para impressora 3d
GEP201706672B (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
WO2018231845A3 (en) SOLID LUBRICANT COMPOSITIONS AND BEARING INCORPORATING THEM